Management considerations in Hürthle cell carcinoma*
References (23)
- et al.
Hürthle cell cancer of the thyroid
Am J Surg
(1975) - et al.
Invasive Hürthle cell carcinoma of the thyroid
Mayo Clin Proc
(1984) - et al.
Prospective management of nodal metastases in differentiated thyroid cancer
Am J Surg
(1991) The oxyphil and C cells of the human thyroid gland
Cancer
(1975)- et al.
Hürthle cell tumor arising in the mediastinal ectopic thyroid and diagnosed by fine needle aspiration: light microscopic and ultrastructural features
Acta Cytol
(1983) - et al.
Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study
Ultrastruct Pathol
(1985) Beitrage zur kenntnis de sekretionsvorganges in der schilddruse
Arch F D Ges physiol
(1894)Beitrage zur Histologi menschlicher Organe: IV, Zunge, V, Mundhohle-Schlundkopf, VI, Oesophagus, VII, Cardia
Sitzungsb d k Akad d Wissensch Mathnaturw Cl Wein
(1897)- et al.
Oncocytes, oncocytosis and oncolytic tumors
Pathology Journal
(1992) - et al.
Oncolytic neoplasms of the thyroid gland
Acta Pathologica Japonica
(1992)
Hürthle cell lesions of the thyroid gland
Surg Gynecol Obstet
Cited by (52)
Hürthle Cell Tumors of the Thyroid
2021, Surgery of the Thyroid and Parathyroid GlandsSurgeon-performed ultrasound predictors of malignancy in patients with Hü rthle cell neoplasms of the thyroid
2013, Journal of Surgical ResearchCitation Excerpt :Hyperplastic nodules accounted for 30% of all patients with HCN. Other studies have reported the incidence of such nonneoplastic nodules from 9% to 66% [22,23]. Furthermore, in this study, the incidence of carcinoma in patients with HCN was 35%, which falls within the 14%–67% incidence range of malignancy reported by other investigators [11,12].
Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging
2011, Seminars in Nuclear MedicineCitation Excerpt :Hürthle cell carcinoma was initially considered a variant of FTC; however, it shows a different oncogenic expression profile than FTC and is therefore now recognized as distinct clinicopathologic entity. It is an uncommon and occasionally aggressive differentiated thyroid malignancy,45 particularly when the primary tumor is widely invasive.4,46 Approximately 3.6% of thyroid cancers are of the Hürthle cell subtype.47
Palliation of advanced thyroid malignancies
2007, Surgical OncologyPositron Emission Tomography and Thyroid Cancer
2007, PET ClinicsCitation Excerpt :FDG-PET is preferred over radioiodine when the tumor cells are known to have low iodine uptake, such as in Hurtle-cell and undifferentiated (anaplastic) thyroid tumors. Hurtle-cell carcinoma has a worse prognosis, compared with papillary and follicular thyroid cancers, and presents unique clinical features, such as higher incidence of distant metastasis and a relatively aggressive clinical course.59–61 The patients with Hurtle-cell thyroid carcinoma are usually monitored with sequential serum Tg measurements, because more than 80% of the patients have noniodine-avid tumor and the clinical utility of radioiodine is limited in this population.
Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm
2006, American Journal of Surgery
- *
Presented at the Fifty-second Annual Meeting of the Central Surgical Association, Cleveland, Ohio, March 9–11, 1995.